Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Das R, Blázquez-Gamero D, Bernstein DI, Gantt S, Bautista O, Beck K, Conlon A, Rosenbloom DIS, Wang D, Ritter M, Arnold B, Annunziato P, Russell KL; V160-002 study group. Das R, et al. Among authors: gantt s. Lancet Infect Dis. 2023 Dec;23(12):1383-1394. doi: 10.1016/S1473-3099(23)00343-2. Epub 2023 Aug 31. Lancet Infect Dis. 2023. PMID: 37660711 Clinical Trial.
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, Smith B, Gantt S, McElhaney JE, Dionne M, van Damme P, Leroux-Roels I, Leroux-Roels G, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson DE, Popovic V, Diaz-Mitoma F; PROTECT Study Group. Vesikari T, et al. Among authors: gantt s. Lancet Infect Dis. 2021 Sep;21(9):1271-1281. doi: 10.1016/S1473-3099(20)30780-5. Epub 2021 May 11. Lancet Infect Dis. 2021. PMID: 33989539 Clinical Trial.
Safety and Immunogenicity of an mRNA-1273 Booster in Children.
Berthaud V, Creech CB, Rostad CA, Carr Q, de Leon L, Dietrich M, Gupta A, Javita D, Nachman S, Pinninti S, Rathore M, Rodriguez CA, Luzuriaga K, Towner W, Yeakey A, Brown M, Zhao X, Deng W, Xu W, Zhou H, Girard B, Kelly R, Slobod K, Anderson EJ, Das R, Miller J, Schnyder Ghamloush S. Berthaud V, et al. Clin Infect Dis. 2024 Dec 17;79(6):1524-1532. doi: 10.1093/cid/ciae420. Clin Infect Dis. 2024. PMID: 39158584 Free PMC article. Clinical Trial.
Vaccine value profile for cytomegalovirus.
Boppana SB, van Boven M, Britt WJ, Gantt S, Griffiths PD, Grosse SD, Hyde TB, Lanzieri TM, Mussi-Pinhata MM, Pallas SE, Pinninti SG, Rawlinson WD, Ross SA, Vossen ACTM, Fowler KB. Boppana SB, et al. Among authors: gantt s. Vaccine. 2023 Nov 3;41 Suppl 2:S53-S75. doi: 10.1016/j.vaccine.2023.06.020. Epub 2023 Oct 6. Vaccine. 2023. PMID: 37806805 Free article.
An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
Langley JM, Gantt S, Halperin SA, Ward B, McNeil S, Ye L, Cai Y, Smith B, Anderson DE, Mitoma FD. Langley JM, et al. Among authors: gantt s. Vaccine. 2024 Jan 25;42(3):713-722. doi: 10.1016/j.vaccine.2023.12.019. Epub 2023 Dec 22. Vaccine. 2024. PMID: 38142214 Free article. Clinical Trial.
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, Garner F, Griffin C, Palanpurwala K, Turner M, Gerber J, Bennett RL, Ali K, Ampajwala M, Berman G, Nayak J, Chronis C, Rizzardi B, Muller WJ, Smith CA, Fuchs G, Hsia D, Tomassini JE, DeLucia D, Reuter C, Kuter B, Zhao X, Deng W, Zhou H, Ramirez Schrempp D, Hautzinger K, Girard B, Slobod K, McPhee R, Pajon R, Aunins A, Das R, Miller JM, Schnyder Ghamloush S; KidCOVE Study Group. Anderson EJ, et al. N Engl J Med. 2022 Nov 3;387(18):1673-1687. doi: 10.1056/NEJMoa2209367. Epub 2022 Oct 19. N Engl J Med. 2022. PMID: 36260859 Free PMC article. Clinical Trial.
Pandemic Stringency Measures and Hospital Admissions for Eating Disorders.
Roumeliotis N, Carwana M, Charland K, Trudeau O, Benigeri M, Diop M, Agostino H, Zinszer K, Amsdr I, Forgeot d'Arc B, Côté S, Basta NE, Fontela P, Gantt S, Klassen TP, Quach C, Doan Q; Pediatric Outcomes Improvement Through Coordination of Research Networks (POPCORN) Investigators. Roumeliotis N, et al. Among authors: gantt s. JAMA Pediatr. 2024 Sep 1;178(9):879-887. doi: 10.1001/jamapediatrics.2024.2044. JAMA Pediatr. 2024. PMID: 38976259 Free PMC article.
147 results